Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Market Closed 09-25 16:00:00 EDT

4.27

-0.07

-1.61%

盘后4.26

-0.01-0.23%

19:30 EDT

High4.40	Low4.26	Vol513.54K
Open4.36	D1 Closing4.34	Amplitude3.34%
Mkt Cap275.71M	Tradable Cap210.13M	Total Shares64.57M
T/O2.20M	T/O Rate1.04%	Tradable Shares49.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.27,"timestamp":1790366400000,"preClose":4.34,"halted":0,"volume":513539,"hourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.27,"latestTime":"19:30 EDT","volume":5366,"amount":22914.15,"timestamp":1790379005685,"change":-0.01,"changeRate":-0.002342,"amplitude":0.002342},"delay":0,"changeRate":-0.01612903225806458,"floatShares":49210000,"shares":64569967,"eps":-0.979559,"marketStatus":"Market Closed","change":-0.07,"latestTime":"09-25 16:00:00 EDT","open":4.36,"high":4.4,"low":4.255,"amount":2203260.8161564,"amplitude":0.03341,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.979559,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.34,"preHourTrading":{"tag":"盘前","latestPrice":4.35,"preClose":4.34,"latestTime":"09:28 EDT","volume":705,"amount":3093.7827315,"timestamp":1790342936001,"change":0.01,"changeRate":0.002304,"amplitude":0.016313},"postHourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.27,"latestTime":"19:30 EDT","volume":5366,"amount":22914.15,"timestamp":1790379005685,"change":-0.01,"changeRate":-0.002342,"amplitude":0.002342},"volumeRatio":0.766161,"impliedVol":1.5652,"impliedVolPercentile":0.6842},"requestUrl":"/m/hq/s/IMRX/wiki","defaultTab":"wiki","newsList":[{"id":"2669467616","title":"Immuneering MAPKeeper-301 Phase 3 Pancreatic Cancer Trial Abstract Wins ESMO 2026 Poster Slot","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467616","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669467616?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:31","pubTimestamp":1790249469,"startTime":"0","endTime":"0","summary":"Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slotImmuneering flagged an ongoing Phase 3 MAPKeeper-301 trial of atebimetinib with chemotherapy in first-line ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL4MqBjZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IMRX","SG9999014013.SGD","BK4585","BK4539","IE00BQXX3D17.EUR","BK4588","IE00BN0W2T93.GBP","NDAQ","BK4139","LU2210149790.SGD","IE00BGHQF748.EUR","BCDF","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","BK4563","SG9999014021.USD","IE00BQXX3F31.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598673","title":"Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598673","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598673?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:30","pubTimestamp":1789039800,"startTime":"0","endTime":"0","summary":"- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359390/0/en/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","IMRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664011558","title":"Immuneering to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664011558","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664011558?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465900,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today ann","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3356257/0/en/immuneering-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMRX","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CANC","IE00BJJMRZ35.SGD","LU0128526141.USD","IMRX","IE00BFTCPJ56.SGD","IE0002141913.USD","LABU","BK4139","BK4581","LU0889565916.HKD","LU0320765992.SGD","IE00B2B36J28.USD","BK4563","IE0009354923.USD","BK4539","XLV","BK4137","LU0029874061.USD","RVMD","IE00BJT1NW94.SGD","BBH","LU0109394709.USD","IE00B4R5TH58.HKD","XBI","IDNA","IE0009355771.USD","BK4588","HCSG","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662674782","title":"Immuneering Enrolls Phase 3 MAPKeeper 301 Trial of Atebimetinib Combo in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662674782","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662674782?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:16","pubTimestamp":1787778980,"startTime":"0","endTime":"0","summary":"Immuneering enrolls Phase 3 MAPKeeper 301 trial of atebimetinib combo in first-line metastatic pancreatic cancerImmuneering highlighted enrollment in its global Phase 3 MAPKeeper 301 trial testing ate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL3Mp2bd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BKPKM429.USD","IMRX","BK4539","SG9999014021.USD","BK4563","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4588","BCDF","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4139","IE00BQXX3D17.EUR","LU2095319765.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657062657","title":"aTyr Pharma Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657062657","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657062657?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:17","pubTimestamp":1786133859,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q2 net loss narrowsOverviewUS biotech firm posted Q2 net loss of $10.3 mln vs loss of $19.5 mln year agoCompany announced 60% workforce reduction to focus on efzofitimod in ILDEnded Q2 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMRX","LU1699723380.USD","BK4563","LU1571399168.USD","UTHR","BK4539","BK4583","EBS","ATYR","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU2324357040.USD","LU0109394709.USD","IBRN","BK4139","IE00B2B36J28.USD","LU2065169927.USD","LU0154245673.USD","XENE","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","LU0154245756.USD","PSIL","IMRX","SBIO","BK4539","GHRS","NBIX","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU2065171311.SGD","LU0823416689.USD","IE0009355771.USD","LU2065171402.SGD","BK4007","BK4563","LU0889565916.HKD","LU2065170008.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633599","title":"HC Wainwright Initiates Immuneering at Buy With $14 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633599","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633599?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:18","pubTimestamp":1786015125,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) has an average rating of buy and mean price target of $18.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563351","title":"Immuneering Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563351?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:16","pubTimestamp":1786014960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657840926","title":"Immuneering Corporation : H.c. Wainwright Initiates Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657840926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657840926?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:08","pubTimestamp":1786010896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nAZN4TC72Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575672","title":"Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575672","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575672?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:47","pubTimestamp":1785962871,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Q2 revenue falls sharply on lower license incomeOverviewU.S. biopharma firm's Q2 revenue fell sharply yr/yr due to prior one-time license revenueCompany posted Q2 net loss as R&D exp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","IMRX","BK4588","LU0889565916.HKD","IBRN","BK4585","BK4139","BK4007","DNTH","EYPT","BK4539","BK4563","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575666","title":"Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575666","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575666?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:46","pubTimestamp":1785962781,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Q2 net loss widens on impairment chargeOverviewUS heart disease therapy developer's Q2 net loss widened, driven by impairment chargeCompany received $10 mln upfront payment from Al","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","LU0889565916.HKD","LU0320765992.SGD","BK4563","TRDA","BK4585","BK4139","ALNY","GNMX","PBE","LU0109394709.USD","BK4548","TNYA","IMRX","LU0114720955.EUR","LU0882574055.USD","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520170","title":"Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520170","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520170?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:13","pubTimestamp":1785960830,"startTime":"0","endTime":"0","summary":"Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone paymentsOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsCompany posted narrower net loss of $21.7 mln, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4563","BK4539","PBE","BK4007","XNCR","BK4139","IMRX","RPRX","IHE","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657352038","title":"Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2657352038","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657352038?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960515,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics Q2 net loss narrows year over yearOverviewUS oncology developer's Q2 net loss narrowed yr/yrCompany presented positive Phase 2 silevertinib results in NSCLC at ASCO 2026Cash","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","IMRX","DNTH","TRDA","BK4539","IBRN","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657549701","title":"Immuneering Expects Cash Runway to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657549701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657549701?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:40","pubTimestamp":1785930027,"startTime":"0","endTime":"0","summary":"Immuneering expects cash runway to fund operations into 2029OverviewUS oncology drug developer's Q2 net loss beat analyst expectations, loss per share met consensusCompany ended Q2 with $182.7 mln in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU0114720955.EUR","LU2242652126.USD","SG9999001440.SGD","TMED","IE00BZ1G4Q59.USD","LU2087621335.USD","LU2089984988.USD","RYTM","LU1934455863.HKD","IBBQ","BK4581","AMGN","LU0432979614.USD","MCK","LU1814569148.SGD","IE00B4R5TH58.HKD","LU0942090050.USD","MEDI","LU0058720904.USD","PBE","BK4566","BK4539","BMED","LU0868494617.USD","LU0965509101.SGD","LU1057294990.SGD","LU0320765992.SGD","IBB","IMRX","LU0823416689.USD","LU1674673428.USD","LU2324357040.USD","PJP","LU0109394709.USD","SG9999015986.USD","BK4550","IE00B2B36J28.USD","LU0861579265.USD","LU1066053197.SGD","LU0203345920.USD","IE0002270589.USD","SG9999015952.SGD","LU1023059063.AUD","GILD","IE00B19Z3581.USD","TBXU","BBH","BIB","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657549728","title":"Immuneering Q2 EPS $(0.27), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657549728","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657549728?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:38","pubTimestamp":1785929921,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60944596/immuneering-q2-eps-0-27-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657499695","title":"Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657499695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657499695?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA2WY7QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4539","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785250","title":"Immuneering publishes preclinical data on atebimetinib in Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785250?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:10","pubTimestamp":1784668216,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, charact...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-publishes-preclinical-data-on-atebimetinib-in-cancer-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-publishes-preclinical-data-on-atebimetinib-in-cancer-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4563","IMRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653788984","title":"Immuneering Flags New Press Release on Atebimetinib Preclinical Study Publication in Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2653788984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653788984?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:10","pubTimestamp":1784664623,"startTime":"0","endTime":"0","summary":"Immuneering flags new press release on atebimetinib preclinical study publication in Cancer ResearchImmuneering disclosed aCancer Researchpublication on atebimetinib showing broad, durable preclinical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL1Pjzrl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4563","IE00B3QW5Z07.USD","IMRX","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","BK4539","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297568","title":"Immuneering Corp : Needham Raises Target Price to $18 from $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297568?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:46","pubTimestamp":1784544415,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.1709},{"period":"3month","weight":-0.1029},{"period":"6month","weight":-0.1391},{"period":"1year","weight":-0.4663},{"period":"ytd","weight":-0.3511}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.4,"avgChangeRate":0.059054},{"month":4,"riseRate":0.2,"avgChangeRate":-0.166499},{"month":5,"riseRate":0.4,"avgChangeRate":0.024846},{"month":6,"riseRate":0.6,"avgChangeRate":0.254483},{"month":7,"riseRate":0.6,"avgChangeRate":-0.012322},{"month":8,"riseRate":0.5,"avgChangeRate":0.165969},{"month":9,"riseRate":0.666667,"avgChangeRate":0.470007},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}